Principal Scientist and Director of CDO Downstream and Development
Introduced to QbD in the early 2000s, Songyoung Kim, principal scientist and director of downstream development at Samsung Biologics, has rigorously implemented QbD-led practices in downstream process development/characterization and tech transfer of biosimilar and drug products at various global biotechs for over 21 years. At Samsung Biologics, he is in charge of designing CDO process development by QbD principles.
Got a Question for Songyoung Kim?
Get in touch using the contact form linked here and we’ll get back to you shortly.
Published Content
Total: 1
Advertisement
